Company intelligence / Profile preview

BioMS Medical Corp.

Edmonton, Alberta, Canadabiomsmedical.com ↗

Ownership: Private
Employees: ~37
Development stage: Other

Overview

BioMS Medical developed dirucotide (MBP8298), a peptide therapeutic for multiple sclerosis. The compound was evaluated in two pivotal phase III clinical trials for secondary progressive MS and a phase II trial for relapsing remitting MS. In December 2007, Eli Lilly licensed global rights to dirucotide, providing significant upfront and milestone payments to BioMS[6][7][10].

Therapeutic areas: Neurology
Modalities: Peptides (MBP8298/dirucotide)
Industry: Biotech

Partnerships

Eli Lilly and Company (global licensing/development partnership for MBP8298/dirucotide)[7]

Beyond the preview

Go deeper on BioMS Medical Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMS Medical Corp..